Pharmaceutical Stocks are Gaining Momentum amid COVID-19 Vaccine Development
07.08.2020, 05:57

Pharmaceutical Stocks are Gaining Momentum amid COVID-19 Vaccine Development

The pharmaceutical industry is gaining momentum as many companies worldwide are seeking the cure from a deadly COVID-19 infection. U.S. President Donald Trump said the vaccine could be developed already by November this year. Many countries like Australia, Japan, South Korea have approved medications that will help infected to recover from the decease. Vaccine, when it appears on the market, will be of a great demand by most of the countries and would boost sales of medications worldwide. Pharmaceutical stocks have performed well since the beginning of last year posting gains of 14.7% compared to the S&P 500's total return of 14.3%, according to the SPDR S&P Pharmaceuticals ETF (XPH) research. 

Here are the three pharmaceutical stocks with the best value, fastest earning growth and the most momentum. 

Moderna has been one of the front-runners within the COVID-19 vaccine race. The company’s vaccine candidate mRNA-1273 could be a particle that heredity encodes a set of informational, based on which cells make proteins and send them to different parts of the body. Moderna’s immunization for COVID-19 appeared it was safe and activated safe reactions in all 45 healthy volunteers within the early-stage consider. Its shares have picked up 28.5% for the past month. 

Pfizer joined powers with German biotech mammoth BioNTech (NTX) to create an antibody for coronavirus. The company has  entered its stage 2/3 security and adequacy clinical consider on 30,000 subjects. Clinical trials has performed well so far and secured the company a $1.95 billion contract with up to 600 million doses of the vaccine to be delivered to the market. Pfizer’s shares have progressed 10.9% within the past month. The Zacks Agreement Research estimate  current-year profit has moved forward 1.4% over the past 60 days. Pfizer carries a Zacks Rank #3 (Hold). 

Gilead Sciences, Inc. GILD in May got an emergency-use authorization from the FDA based on the medication comes about from two clinical trials: one conducted by the NIAID and the other by itself. The company’s anticipated profit development rate for following year is 4.1%. The Zacks Agreement appraise for current-year profit has progressed 3.8% over the past 30 days. Shares of the company have picked up 9.7% year to date.

  • Ime: Hussain Shabbir
Kote
Simbol Bid Ask Vreme
AUDUSD
EURUSD
GBPUSD
NZDUSD
USDCAD
USDCHF
USDJPY
XAGEUR
XAGUSD
XAUUSD

© 2000-2022. Sva prava zaštićena.

Sajt je vlasništvo kompanije Teletrade D.J. Limited 20599 IBC 2012 (First Floor, First St. Vincent Bank Ltd Building, James Street, Kingstown, St. Vincent and the Grenadines).

Svi podaci koji se nalaze na sajtu ne predstavljaju osnovu za donošenje investicionih odluka, već su informativnog karaktera.

Politika sprečavanja pranja novca

Upozorenje o rizicima

Izvršenje trgovinskih operacija sa finansijskim instrumentima upotrebom marginalne trgovine pruža velike mogućnosti i omogućava investitorima ostvarivanje visokih prihoda. Međutim, takav vid trgovine povezan je sa potencijalno visokim nivoom rizika od gubitka sredstava. Проведение торговых операций на финансовых рынках с маржинальными финансовыми инструментами открывает широкие возможности, и позволяет инвесторам, готовым пойти на риск, получать высокую прибыль, но при этом несет в себе потенциально высокий уровень риска получения убытков. Iz tog razloga je pre započinjanja trgovine potrebno odlučiti o izboru odgovarajuće investicione strategije, uzimajući u obzir raspoložive resurse.

Politika poverenja

Upotreba informacija: U slučaju potpunog ili delimičnog preuzimanja i daljeg korišćenja materijala koji se nalazi na sajtu, potrebno je navesti link odgovarajuće stranice na sajtu kompanije TeleTrade-a kao izvora informacija. Upotreba materijala na internetu mora biti praćena hiper linkom do web stranice teletrade.org. Automatski uvoz materijala i informacija sa stranice je zabranjen.

Ako imate bilo kakvih pitanja, obratite nam se pr@teletrade.global.

Feedback
Lajv čet E-mail
Povratak na vrh
Izaberi lokaciju / jezik